Outcomes of idiopathic chronic large pericardial effusion.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
03 2019
Historique:
received: 30 04 2018
revised: 24 08 2018
accepted: 30 08 2018
pubmed: 3 10 2018
medline: 3 5 2019
entrez: 3 10 2018
Statut: ppublish

Résumé

Aim of this paper is to evaluate the outcomes of 'idiopathic' chronic large pericardial effusions without initial evidence of pericarditis. All consecutive cases of idiopathic chronic large pericardial effusions evaluated from 2000 to 2015 in three Italian tertiary referral centres for pericardial diseases were enrolled in a prospective cohort study. The term 'idiopathic' was applied to cases that performed a complete diagnostic evaluation to exclude a specific aetiology. A clinical and echocardiographic follow-up was performed every 3-6 months. 100 patients were included (mean age 61.3±14.6 years, 54 females, 44 patients were asymptomatic according to clinical evaluation) with a mean follow-up of 50 months. The baseline median size of the effusion (evaluated as the largest end-diastolic echo-free space) was 25 mm (IQR 8) and decreased to a mean value of 7 mm (IQR 19; p<0.0001) with complete regression in 39 patients at the end of follow-up. There were no new aetiological diagnoses. Adverse events were respectively: cardiac tamponade in 8 patients (8.0%), pericardiocentesis in 30 patients (30.0%), pericardial window in 12 cases (12.0%) and pericardiectomy in 3 patients (3.0%). Recurrence-free survival and complications-free survival was better in patients treated without interventions (log rank p=0.0038). The evolution of 'idiopathic' chronic large pericardial effusions is usually benign with reduction of the size of the effusion in the majority of cases, and regression in about 40% of cases. The risk of cardiac tamponade is 2.2%/year and recurrence/complications survival was better in patients treated conservatively without interventions.

Identifiants

pubmed: 30274986
pii: heartjnl-2018-313532
doi: 10.1136/heartjnl-2018-313532
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

477-481

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Massimo Imazio (M)

University Cardiology, Cardiovascular and Thoracic Department and Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, Torino, Italy.

George Lazaros (G)

Department of Cardiology, Hippokration General Hospital, Athens, Greece.

Anna Valenti (A)

Department of Internal Medicine, Ospedale Papa Giovanni XXIII, Bergamo, Italy.

Caterina Chiara De Carlini (CC)

Department of Cardiology, San L. Mandic Hospital, Merate, Italy.

Stefano Maggiolini (S)

Department of Cardiology, San L. Mandic Hospital, Merate, Italy.

Emanuele Pivetta (E)

Cancer Epidemiology Unit, Emergency Medicine Division, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino and University of Turin, Torino, Italy.

Carla Giustetto (C)

University Cardiology, Cardiovascular and Thoracic Department and Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, Torino, Italy.

Dimitris Tousoulis (D)

Department of Cardiology, Hippokration General Hospital, Athens, Greece.

Yehuda Adler (Y)

Sackler Faculty of Medicine, University of Tel Aviv, Tel Aviv, Israel.

Mauro Rinaldi (M)

University Cardiology, Cardiovascular and Thoracic Department and Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, Torino, Italy.

Antonio Brucato (A)

Department of Internal Medicine, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Internal Medicine, ASST Fatebenefratelli Sacco di Milano and University of Milano, Milano, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH